Gastric Cancer Clinical Trial
Official title:
Cytoreductive Surgery and Intraperitoneal Chemotherapy for Stomach CAncer: a Feasibility Study
Rationale: For patients with peritoneal metastases of gastric origin, there is no consensus
on the optimal treatment strategy. Several Asian and Western studies demonstrated
hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CS) to result in
a prolonged survival compared to palliative systemic treatment. Morbidity and mortality rates
of HIPEC and CS appear to be acceptable. In the Netherlands, this treatment is not yet
introduced, therefore patients with peritoneal metastases of gastric origin are precluded
from surgery and will be treated with palliative chemotherapy or best support of care.
Objective: To assess the safety and feasibility of HIPEC and CS in Western patients with
peritoneal metastases of gastric cancer, in terms of morbidity and mortality. Secondary
objective is to determine the effect on survival and recurrence.
Study design: Mono centre prospective phase II single-arm feasibility study.
Study population: Western patients diagnosed with resectable (cT1-4b, N1-3) gastric cancer
with clinical or pathologically proven peritoneal metastases without distant metastases.
Intervention: Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Cytoreductive Surgery
(CS) with Cisplatin.
Main study parameters/endpoints: Primary outcome is the safety and feasibility of the
intervention, measured by the percentage of overall surgical complications grade ≥3 as stated
by the Common Terminology Criteria for Adverse Events. Secondary outcomes are intraoperative
events, postoperative morbidity and mortality, postoperative recovery, including quality of
life, and disease free- and overall survival.
Nature and extent of the burden and risks associated with participation, benefit and group
relatedness: The additional burden for the patient mainly consists of HIPEC and
CS.Furthermore, patients will undergo additional staging in order to exclude unresectable
disease, and neoadjuvant chemotherapy regimen (3 drugs) instead of a palliative chemotherapy
regimen (2 drugs). Postoperative care and outpatient visits are performed according to
current protocols on HIPEC and CS for colon cancer and nation-wide protocols on gastric
cancer surgery. The study is associated with a high risk classification. As there is a
potential survival benefit, a small chance for curation and possibly a higher quality of
life, we consider the additional burden and risks justified. This study is designed as a one
group study, which eliminates group relatedness.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05551416 -
The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
|
||
| Recruiting |
NCT05518929 -
Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients
|
Phase 4 | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03219593 -
Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Recruiting |
NCT05536102 -
The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
|
Phase 2 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
| Active, not recruiting |
NCT04082364 -
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
|
Phase 2/Phase 3 | |
| Withdrawn |
NCT03766607 -
Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer
|
Phase 2 | |
| Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
| Completed |
NCT01924533 -
Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.
|
Phase 3 | |
| Terminated |
NCT01641939 -
A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
| Active, not recruiting |
NCT04908813 -
Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04249739 -
Pembrolizumab + Capecitabine／Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive
|
Phase 2 | |
| Recruiting |
NCT05514158 -
To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)
|
Phase 1 | |
| Recruiting |
NCT04931654 -
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 |